A perspective on the treatment of lyme borreliosis

Benjamin J. Luft, P. D. Gorevic, John Halperin, David J. Volkman, Raymond J. Dattwyler

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Lymeborreliosis has become the most common tick-borne infection in the United States. Although both β-lactam and tetracycline antibiotics have been shown to be effective in the treatment of this spirochetosis, the development of optimal therapeutic modalities has been hampered by the lack of reliable microbiologic or immunologic criteria for the diagnosis or cure of this infection. In vitro sensitivity studies have been performed by several laboratories, but there has been no standardization of the methodology for measuring either inhibitory or bactericidal levels. Clinical studies have documented the efficacy of antibiotics, but therapy has failed in as many as 50% of cases of chronic infection. Although new antibiotic regimens appear promising, the optimal treatment of this infectious disease remains to be determined. In this report wereview the clinical and experimental rationale for the antibiotic regimens that we currently use and the need for a more standardized approach to treatment trials.

Original languageEnglish (US)
Pages (from-to)S1518-S1525
JournalReviews of Infectious Diseases
Volume11
DOIs
StatePublished - Jan 1 1989

Fingerprint

Lyme Disease
Anti-Bacterial Agents
Tick-Borne Diseases
Lactams
Immunologic Tests
Infection
Tetracycline
Communicable Diseases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)

Cite this

Luft, Benjamin J. ; Gorevic, P. D. ; Halperin, John ; Volkman, David J. ; Dattwyler, Raymond J. / A perspective on the treatment of lyme borreliosis. In: Reviews of Infectious Diseases. 1989 ; Vol. 11. pp. S1518-S1525.
@article{64454975c40a4a2aace31a13941ce3f7,
title = "A perspective on the treatment of lyme borreliosis",
abstract = "Lymeborreliosis has become the most common tick-borne infection in the United States. Although both β-lactam and tetracycline antibiotics have been shown to be effective in the treatment of this spirochetosis, the development of optimal therapeutic modalities has been hampered by the lack of reliable microbiologic or immunologic criteria for the diagnosis or cure of this infection. In vitro sensitivity studies have been performed by several laboratories, but there has been no standardization of the methodology for measuring either inhibitory or bactericidal levels. Clinical studies have documented the efficacy of antibiotics, but therapy has failed in as many as 50{\%} of cases of chronic infection. Although new antibiotic regimens appear promising, the optimal treatment of this infectious disease remains to be determined. In this report wereview the clinical and experimental rationale for the antibiotic regimens that we currently use and the need for a more standardized approach to treatment trials.",
author = "Luft, {Benjamin J.} and Gorevic, {P. D.} and John Halperin and Volkman, {David J.} and Dattwyler, {Raymond J.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1093/clinids/11.Supplement_6.S1518",
language = "English (US)",
volume = "11",
pages = "S1518--S1525",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

A perspective on the treatment of lyme borreliosis. / Luft, Benjamin J.; Gorevic, P. D.; Halperin, John; Volkman, David J.; Dattwyler, Raymond J.

In: Reviews of Infectious Diseases, Vol. 11, 01.01.1989, p. S1518-S1525.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A perspective on the treatment of lyme borreliosis

AU - Luft, Benjamin J.

AU - Gorevic, P. D.

AU - Halperin, John

AU - Volkman, David J.

AU - Dattwyler, Raymond J.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Lymeborreliosis has become the most common tick-borne infection in the United States. Although both β-lactam and tetracycline antibiotics have been shown to be effective in the treatment of this spirochetosis, the development of optimal therapeutic modalities has been hampered by the lack of reliable microbiologic or immunologic criteria for the diagnosis or cure of this infection. In vitro sensitivity studies have been performed by several laboratories, but there has been no standardization of the methodology for measuring either inhibitory or bactericidal levels. Clinical studies have documented the efficacy of antibiotics, but therapy has failed in as many as 50% of cases of chronic infection. Although new antibiotic regimens appear promising, the optimal treatment of this infectious disease remains to be determined. In this report wereview the clinical and experimental rationale for the antibiotic regimens that we currently use and the need for a more standardized approach to treatment trials.

AB - Lymeborreliosis has become the most common tick-borne infection in the United States. Although both β-lactam and tetracycline antibiotics have been shown to be effective in the treatment of this spirochetosis, the development of optimal therapeutic modalities has been hampered by the lack of reliable microbiologic or immunologic criteria for the diagnosis or cure of this infection. In vitro sensitivity studies have been performed by several laboratories, but there has been no standardization of the methodology for measuring either inhibitory or bactericidal levels. Clinical studies have documented the efficacy of antibiotics, but therapy has failed in as many as 50% of cases of chronic infection. Although new antibiotic regimens appear promising, the optimal treatment of this infectious disease remains to be determined. In this report wereview the clinical and experimental rationale for the antibiotic regimens that we currently use and the need for a more standardized approach to treatment trials.

UR - http://www.scopus.com/inward/record.url?scp=0024730951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024730951&partnerID=8YFLogxK

U2 - 10.1093/clinids/11.Supplement_6.S1518

DO - 10.1093/clinids/11.Supplement_6.S1518

M3 - Article

VL - 11

SP - S1518-S1525

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -